ALX Oncology Ownership | Who Owns ALX Oncology?

Overview ForecastFinancials Chart Transcripts

ALX Oncology Ownership Summary

ALX Oncology is owned by 54.40% institutional investors, 2.44% insiders, and 43.16% retail investors. Venbio partners is the largest institutional shareholder, holding 18.15% of ALXO shares. HBM Healthcare Investments AG Ord is the top mutual fund, with 8.42% of its assets in ALX Oncology shares.

ALXO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	ALX Oncology	54.40%	2.44%	43.16%
Sector	Healthcare Stocks	492.67%	11.09%	-403.76%
Industry	Biotech Stocks	295.31%	11.22%	-206.53%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Venbio partners	9.70M	18.15%	$17.75M
Redmile group	3.33M	6.24%	$6.10M
Blackrock	2.69M	5.36%	$16.21M
Almitas capital	2.54M	4.75%	$4.64M
Millennium management	2.13M	4.04%	$3.56M
Vanguard group	1.53M	2.86%	$2.80M
Acadian asset management	1.22M	2.28%	$2.23M
Driehaus capital management	795.78K	1.49%	$1.46M
Two sigma advisers, lp	719.80K	1.35%	$1.32M
Ameriprise financial	652.90K	1.22%	$1.19B

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Venbio partners	9.70M	10.06%	$17.75M
Almitas capital	2.54M	1.06%	$4.64M
Redmile group	3.33M	0.59%	$6.10M
Privium fund management b.v.	509.06K	0.17%	$931.58K
Affinity asset advisors	100.00K	0.07%	$603.00K
Hc advisors	21.85K	0.03%	$39.99K
Gsa capital partners llp	88.17K	0.01%	$161.00K
Driehaus capital management	795.78K	0.01%	$1.46M
Nan fung trinity (hk)	41.95K	0.01%	$76.77K
Jsf financial	17.50K	0.01%	$32.02K

Top Buyers

Holder	Shares	% Assets	Change
Driehaus capital management	795.78K	0.01%	795.78K
Ameriprise financial	652.90K	0.00%	652.90K
Blackrock	2.69M	0.00%	466.06K
Jacobs levy equity management	232.02K	0.01%	232.02K
Two sigma investments, lp	606.67K	0.00%	128.74K

Top Sellers

Holder	Shares	% Assets	Change
Vivo capital	-	-	-4.03M
Vestal point capital, lp	-	-	-3.60M
Tang capital management	-	-	-3.16M
Cormorant asset management, lp	-	-	-3.14M
Orbimed advisors	-	-	-1.89M

New Positions

Holder	Shares	% Assets	Change	Value
Driehaus capital management	795.78K	0.01%	795.78K	$1.46M
Ameriprise financial	652.90K	0.00%	652.90K	$1.19B
Jacobs levy equity management	232.02K	0.01%	232.02K	$1.40M
Affinity asset advisors	100.00K	0.07%	100.00K	$603.00K
Ieq capital	92.23K	0.00%	92.23K	$168.79K

Sold Out

Holder	Change
Allspring global investments	-2.00
Farther finance advisors	-4.00
Creekmur asset management	-4.00
Gamma investing	-12.00
True wealth design	-15.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	63	-26.74%	29,075,912	-13.08%	54	1.38%	20	-39.39%	32	10.34%
Mar 31, 2025	86	-7.53%	34,801,922	-15.26%	65	1.07%	34	-35.85%	29	38.10%
Dec 31, 2024	93	-2.11%	41,059,279	-9.68%	77	1.05%	52	-10.34%	21	-4.55%
Sep 30, 2024	95	-18.80%	45,459,170	-6.37%	86	0.92%	58	-15.94%	22	-15.38%
Jun 30, 2024	117	4.46%	48,553,785	6.04%	96	1.16%	69	32.69%	26	-16.13%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
HBM Healthcare Investments AG Ord	4.50M	8.42%	-
Vanguard US Total Market Shares ETF	984.59K	1.84%	-
Vanguard Total Stock Mkt Idx Inv	963.53K	1.80%	-21.06K
Fidelity Select Biotechnology	835.50K	1.58%	-
Fidelity Stock Selector Small Cap	837.11K	1.57%	10.71K
Fidelity Series Small Cap Opps	769.53K	1.44%	-
Fidelity Small Cap Value Fund	678.40K	1.29%	-
Biotech Growth Ord	512.26K	0.97%	105.00K
Fidelity Small Cap Growth	432.37K	0.82%	-1.26M
Fidelity Small Cap Index	348.14K	0.65%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 17, 2025	Lettmann Jason	CHIEF EXECUTIVE OFFICER	Buy	$76.89K
Sep 16, 2025	Lettmann Jason	CHIEF EXECUTIVE OFFICER	Buy	$22.46K
Aug 18, 2025	Shantharam Harish	Chief Financial Officer	Buy	$58.40K
Aug 15, 2025	Pinto Shelly	SVP, FINANCE AND CAO	Sell	$391.28
Aug 15, 2025	Lettmann Jason	CHIEF EXECUTIVE OFFICER	Sell	$1.53K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	-
2025 Q3	3	3
2025 Q2	-	1
2025 Q1	-	4
2024 Q4	1	2

ALXO Ownership FAQ

Who Owns ALX Oncology?

ALX Oncology shareholders are primarily institutional investors at 54.40%, followed by 2.44% insiders and 43.16% retail investors. The average institutional ownership in ALX Oncology's industry, Biotech Stocks , is 295.31%, which ALX Oncology falls below.

Who owns the most shares of ALX Oncology?

ALX Oncology’s largest shareholders are Venbio partners (9.7M shares, 18.15%), Redmile group (3.33M shares, 6.24%), and Blackrock (2.69M shares, 5.36%). Together, they hold 29.75% of ALX Oncology’s total shares outstanding.

Does Blackrock own ALX Oncology?

Yes, BlackRock owns 5.36% of ALX Oncology, totaling 2.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 16.21M$. In the last quarter, BlackRock increased its holdings by 466.06K shares, a 20.98% change.

Who is ALX Oncology’s biggest shareholder by percentage of total assets invested?

Venbio partners is ALX Oncology’s biggest shareholder by percentage of total assets invested, with 10.06% of its assets in 9.7M ALX Oncology shares, valued at 17.75M$.

Who is the top mutual fund holder of ALX Oncology shares?

HBM Healthcare Investments AG Ord is the top mutual fund holder of ALX Oncology shares, with 8.42% of its total shares outstanding invested in 4.5M ALX Oncology shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools